Home › Down Syndrome › Ohio › Cincinnati
Down Syndrome clinical trials in Cincinnati, OH
5 studies for Down Syndrome are looking for participants at sites in and around Cincinnati (within about 30 miles). Open a study to see who can join and how to contact the study team.
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
RecruitingPhase 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
RecruitingObservational studyHealthy volunteers welcome
- Cincinnati Childrens Hospital Medical Center, Cincinnati
Trial-Ready Cohort-Down Syndrome (TRC-DS)
RecruitingObservational study
- University of Cincinnati, Cincinnati
Comparison of a Demand Oxygen Delivery
RecruitingHealthy volunteers welcome
- Cincinnati Children's Hospital Medical Center, Cincinnati
Down Syndrome Obstructive Sleep Apnea
RecruitingPhase 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
About Down Syndrome
About 1 in 700 babies are born with the birth defect known as Down Syndrome. Learn about the different Down Syndrome types and related health issues.
More about Down Syndrome on MedlinePlus
Down Syndrome trials in other cities
- Aurora, CO7 studies
- Durham, NC6 studies
- Houston, TX6 studies
- Phoenix, AZ6 studies
- Philadelphia, PA5 studies
- Kansas City, KS5 studies
- Cleveland, OH5 studies
- Nashville, TN5 studies
- Ann Arbor, MI5 studies
- Orlando, FL5 studies
- Orange, CA4 studies
- Seattle, WA4 studies
Other studies in Cincinnati
- Non-Small Cell Lung Cancer35 studies
- Cancer (all types)28 studies
- Breast Cancer25 studies
- Heart Failure24 studies
- Colorectal Cancer21 studies
- Acute Myeloid Leukemia20 studies
- Metastatic Cancer20 studies
- Lung Cancer19 studies
- Obesity19 studies
- Ovarian Cancer19 studies
- Prostate Cancer18 studies
- Melanoma17 studies
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.